News Roundup: Patient Vaccines, NACDS Total Store Expo Success

Here’s a roundup of the latest news coverage from Drug Topics®.

Immunocompromised Patients and COVID-19 Vaccine Responses

Drug Topics® sat down with Dr. Daniel Streetman, PharmD, to discuss patients with compromised immune systems and reported responses to COVID-19 vaccines and others.

https://www.drugtopics.com/view/immunocompromised-patients-and-covid-19-vaccine-responses

Mosunetuzumab Evokes Strong Response in Elderly Population With DLBCL

Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.

https://www.drugtopics.com/view/mosunetuzumab-evokes-strong-response-in-elderly-population-with-dlbcl

ThoughtSpot 2021 Series: Reducing Health Disparities

As part of our ThoughtSpot 2021 podcast series, guest host Dr. Lonie Haynes leads the conversation with diversity experts on how pharmacists can work to reduce health disparities.

https://www.drugtopics.com/view/thoughtspot-2021-series-reducing-health-disparities

Part 1: Tune into Consumer Demands to Achieve Success in Your Pharmacy

“If you follow the shopper, you will see the future,” said Wendy Liebmann, CEO and chief shopper at WSL Strategic Retail, during a session at the 2021 NACDS Total Store Expo.

https://www.drugtopics.com/view/part-1-tune-into-consumer-demands-to-achieve-success-in-your-pharmacy

Half of pediatric opioid prescriptions are high risk

Many pediatric opioid prescriptions are high risk and leave children at risk of overdose and side effects like constipation.

https://www.drugtopics.com/view/half-of-pediatric-opioid-prescriptions-are-high-risk

NACDS Total Store Expo 2021 Highlights Pandemic Successes, the Future of Pharmacy

https://www.drugtopics.com/view/nacds-total-store-expo-2021-highlights-pandemic-successes-the-future-of-pharmacy

Pfizer-BioNTech Becomes First COVID-19 Vaccine to be Fully Approved by the FDA

The FDA EUA for the COVID-19 vaccine will remain in effect for those 12 to 15 years of age and for the administration of a third dose.

https://www.drugtopics.com/view/pfizer-biontech-becomes-first-covid-19-vaccine-to-be-fully-approved-by-the-fda